Abstract
This study presents proof of concept assays to validate gold nanoparticles loaded with the bacterial peptide 91–99 of the listeriolysin O toxin (GNP-LLO91–99 nanovaccines) as immunotherapy for bladder tumors. GNP-LLO91–99 nanovaccines showed adjuvant abilities as they induce maturation and activation of monocyte-derived dendritic cells (MoDCs) to functional antigen-presenting cells in healthy donors and patients with melanoma or bladder cancer (BC), promoting a Th1 cytokine pattern. GNP-LLO91–99 nanovaccines were also efficient dendritic cell inducers of immunogenic tumor death using different bladder and melanoma tumor cell lines. The establishment of a pre-clinical mice model of subcutaneous BC confirmed that a single dose of GNP-LLO91–99 nanovaccines reduced tumor burden 4.7-fold and stimulated systemic Th1-type immune responses. Proof of concept assays validated GNP-LLO91–99 nanovaccines as immunotherapy by comparison to anti-CTLA-4 or anti-PD-1 antibodies. In fact, GNP-LLO91–99 nanovaccines increased percentages of CD4+ and CD8+ T cells, B cells, and functional antigen-presenting DCs in tumor-infiltrated lymphocytes, while they reduced the levels of myeloid-derived suppressor cells (MDSC) and suppressor T cells (Treg). We conclude that GNP-LLO91–99 nanovaccines can work as monotherapies or combinatory immunotherapies with anti-CTLA-4 or anti-PD-1 antibodies for solid tumors with high T cell infiltration, such as bladder cancer or melanoma.
Funding Information
  • the CICYT program of the Ministry of Science and Innovation (SAF2012-34203, CA-16231, DTS18-00022, PI19-01580, INNVAL17/01, CA-18103)
  • European FEDER funds “A new way of making Europe” and the COST European action ENOVA (SAF2012-34203, CA-16231, DTS18-00022, PI19-01580, INNVAL17/01, CA-18103)
  • Instituto de Salud Carlos III (SAF2012-34203, CA-16231, DTS18-00022, PI19-01580, INNVAL17/01, CA-18103)
  • the Bio-Health Research Program of Cantabria Government (SAF2012-34203, CA-16231, DTS18-00022, PI19-01580, INNVAL17/01, CA-18103)
  • MIUR-Italy (“Progetto Dipartimenti di Eccellenza 2018–2022”, allocated to Department of Chemistry “Ugo Schiff”) (SAF2012-34203, CA-16231, DTS18-00022, PI19-01580, INNVAL17/01, CA-18103)
  • the COST European action INNOGLY (SAF2012-34203, CA-16231, DTS18-00022, PI19-01580, INNVAL17/01, CA-18103)

This publication has 33 references indexed in Scilit: